5
iSERA Lifesciences
COVIDHLTD NSE
iSERA Lifesciences
Information TechnologyNSE: COVIDHLTD BSE: 534920 Computer Software & Consulting
Key Fundamentals
MicrocapComputer Software & ConsultingInformation TechnologyMarket Cap
₹121 Cr
Volatility
High Risk
P/E Ratio
-2,055.7
EBITDA
₹0.50 Cr
Return on Equity
-8.82%
Debt to Equity
0.2
Book Value
₹9.81
52W High
₹143.9
52W Low
₹6.4
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- Stock is trading at 14.7 times its book value
- Company has high debtors of 337 days.
- Promoter holding has decreased over last 3 years: -41.4%
Growth Rate
Revenue Growth
-23.51% lower than
3Y
Net Income Growth
-146% lower than
3Y
Cash Flow Change
49.23% higher than
3Y
ROE
-721% higher than
3Y
ROCE
22.74% higher than
3Y
EBITDA Margin (Avg.)
32.62% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.19 | 1.16 | 0 |
| Expenses | 0.01 | 0.02 | 0.01 | 0.07 | 0.01 | 0.01 | 0.07 | 0.04 | 0.02 | 0 | 0.47 | 0.59 | 0.34 |
| Operating Profit | -0.01 | -0.02 | -0.01 | -0.07 | -0.01 | -0.01 | -0.07 | -0.04 | -0.02 | 0 | -0.28 | 0.57 | -0.34 |
| OPM % | — | — | — | — | — | — | — | — | — | — | -147.37% | 49.14% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.27 | 0 | 0.01 | 0 | 0.06 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.01 | -0.02 | -0.01 | -0.07 | -0.01 | -0.01 | -0.07 | 0.23 | -0.02 | 0.01 | -0.28 | 0.63 | -0.34 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 12.7% | 0% |
| Net Profit | -0.01 | -0.02 | -0.01 | -0.07 | -0.01 | -0.01 | -0.07 | 0.23 | -0.02 | 0.01 | -0.28 | 0.55 | -0.34 |
| EPS in Rs | 0 | 0 | 0 | -0.08 | -0.01 | -0.01 | -0.08 | 0.27 | -0.02 | 0.01 | -0.33 | 0.65 | -0.4 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.9 | 25.5 | 21.36 | 28.92 | 12.3 | 2.13 | 2.13 | 0 | 0 | 0 | 0.27 | 1.3 | 1.35 |
| Expenses | 10.28 | 25.14 | 20.92 | 28.46 | 11.98 | 2.19 | 0.19 | 0.11 | 0.11 | 0.09 | 0.13 | 1.03 | 1.4 |
| Operating Profit | 0.62 | 0.36 | 0.44 | 0.46 | 0.32 | -0.06 | 1.94 | -0.11 | -0.11 | -0.09 | 0.14 | 0.27 | -0.05 |
| OPM % | 5.69% | 1.41% | 2.06% | 1.59% | 2.6% | -2.82% | 91.08% | — | — | — | 51.85% | 20.77% | -3.7% |
| Other Income | 0 | -12.61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.07 | 0.07 |
| Interest | 0 | 0.16 | 0.2 | 0.27 | 0.23 | 0.22 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.5 | 0.08 | 0.21 | 0.15 | 0.08 | 0.12 | 0.12 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.12 | -12.49 | 0.03 | 0.04 | 0.01 | -0.4 | 1.8 | -0.11 | -0.11 | -0.09 | 0.14 | 0.34 | 0.02 |
| Tax % | 0% | 0.4% | 100% | 25% | 200% | 5% | 1.11% | 0% | 0% | 0% | 14.29% | 23.53% | — |
| Net Profit | 0.12 | -12.54 | 0 | 0.04 | -0.02 | -0.42 | 1.78 | -0.11 | -0.11 | -0.09 | 0.12 | 0.26 | -0.06 |
| EPS in Rs | 0 | -0.46 | 0 | 0 | 0 | -0.02 | 0.06 | 0 | 0 | -0.11 | 0.14 | 0.31 | -0.07 |
| Div. Payout % | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.6 | 10.6 | 10.6 | 10.6 | 10.6 | 10.6 | 10.6 | 0.3 | 0.3 | 0.32 | 0.32 | 8.41 |
| Reserves | 2.44 | -10.1 | -10.09 | -10.05 | -10.07 | -10.49 | -10.71 | -0.31 | -0.42 | -0.54 | -0.42 | -0.16 |
| Borrowings | 4.97 | 6.15 | 6.83 | 7.49 | 7.53 | 6.56 | 2.02 | 0 | 0.13 | 0.18 | 1.61 | 1.66 |
| Other Liabilities | 2.54 | 4.61 | 5.57 | 8.19 | 4.12 | 3.81 | 2.59 | 0.02 | 0.04 | 0.1 | 0.05 | 0.65 |
| Total Liabilities | 20.55 | 11.26 | 12.91 | 16.23 | 12.18 | 10.48 | 4.5 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
| Fixed Assets | 6.65 | 0.48 | 0.44 | 0.45 | 0.75 | 0.62 | 0.43 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 1.96 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 7.74 | 10.78 | 12.47 | 15.78 | 11.43 | 9.86 | 4.07 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
| Total Assets | 20.55 | 11.26 | 12.91 | 16.23 | 12.18 | 10.48 | 4.5 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.5 | 0.81 | -0.63 | -0.51 | 0.34 | 0.97 | 4.45 | -0.3 | -0.12 | -0.06 | -1.4 | -5.35 |
| Investing | -1.16 | -0.4 | -0.16 | -0.16 | -0.38 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0.06 |
| Financing | 0.69 | -0.42 | 0.77 | 0.66 | 0.04 | -0.97 | -4.55 | 0.3 | 0.13 | 0.06 | 1.42 | 8.14 |
| Net Cash Flow | 0.04 | -0.01 | -0.02 | -0.01 | 0 | 0 | -0.01 | 0 | 0 | 0 | 0.02 | 2.85 |
| Free Cash Flow | -0.78 | 0.41 | -0.79 | -0.67 | -0.04 | 0.97 | 4.55 | -0.3 | -0.12 | -0.06 | -1.4 | -5.35 |
| CFO/OP | 81 | 225 | -143 | -109 | 112 | -1,650 | 229 | 273 | 109 | 67 | -986 | -1,952 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 193 | 123 | 175 | 178 | 297 | 1,470 | 499 | — | — | — | 419 | 337 |
| Inventory Days | — | — | 0 | 0 | 0 | 0 | — | — | — | — | — | — |
| Cash Conversion Cycle | 193 | 123 | 175 | 178 | 297 | 1,470 | 499 | — | — | — | 419 | 337 |
| Working Capital Days | 174 | 65.13 | 91.59 | 73.58 | 170 | 1,042 | 260 | — | — | — | 351 | 225 |
| ROCE % | 0.68% | 2.27% | 3.29% | 4.03% | 2.98% | -2.44% | 42.42% | -11.58% | — | — | 19.05% | 5.95% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view iSERA Lifesciences insights
49 extracted metrics + investor summaries across FY08–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Newspaper Publication
22 Apr - Submission of Newspaper Advertisement of Postal Ballot Notice pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. 22 Apr - Submission of Newspaper Advertisement of Postal Ballot Notice pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
14h - Submission of Newspaper Advertisement of Postal Ballot Notice pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. 14h - Submission of Newspaper Advertisement of Postal Ballot Notice pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.
3
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
21 Apr - Board approved acquiring iSERA Biological for Rs78.00 crore via 1:1 share swap on 21 April 2026. 21 Apr - Board approved acquiring iSERA Biological for Rs78.00 crore via 1:1 share swap on 21 April 2026.
4
Announcement under Regulation 30 (LODR)-Preferential Issue
21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, preferential issue of 1.61 crore shares, capital increase. 21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, preferential issue of 1.61 crore shares, capital increase.
5
Revised Outcome Of The Meeting Of The Board Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) ('The Company') Pursuant To Regulation 29 And 30 Of The SEBI (LODR) Regulations, 2015.
21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, 1:1 issue of 1.61 crore shares on Apr 21, 2026. 21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, 1:1 issue of 1.61 crore shares on Apr 21, 2026.
Frequently Asked Questions about iSERA Lifesciences
What does iSERA Lifesciences Ltd do?
Incorporated in 1993, Covidh Technologies Ltd is engaged in IT/ITES business.[1]
Where is iSERA Lifesciences Ltd (534920) listed?
iSERA Lifesciences Ltd trades as COVIDHLTD on the NSE and under code 534920 on the BSE.
Which sector does iSERA Lifesciences Ltd belong to?
iSERA Lifesciences Ltd is classified under the Information Technology sector, in the Computer Software & Consulting industry.
What is the market capitalisation of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd has a market capitalisation of ₹121 Cr, which places it in the Small Cap band.
What is the PE ratio of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd trades at a PE ratio of -2055.70, against a book value of ₹9.81 per share.
What is the 52-week high and low of iSERA Lifesciences Ltd?
Over the last 52 weeks iSERA Lifesciences Ltd has traded between ₹6.4 and ₹143.9.
What is the Return on Equity (ROE) of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd reported a return on equity of -8.82%. Its debt-to-equity ratio is 0.20.
Company Information
Incorporated in 1993, Covidh Technologies Ltd is engaged in IT/ITES business.[1]
Website covidh.co.in
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/534920.md for iSERA Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.